This article is a response to a commentary on a previous case report regarding dual β-lactam success in Mycobacterium abscessus infections. While the original case report demonstrated positive outcomes, this response emphasizes the need for caution in interpreting such results. It highlights the complex nature of M. abscessus, particularly its inducible β-lactamase (BlaMab) and potential for resistance development. The authors advocate for rigorous susceptibility testing, including time-kill assays, and careful consideration of host factors and clinical context before broadly applying dual β-lactam therapies. Teaching point: Interpreting treatment success for complex pathogens like Mycobacterium abscessus requires caution, comprehensive susceptibility testing, and consideration of resistance mechanisms.